Aurobindo Pharma’s Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations

At the conclusion of the inspection, the US FDA issued a Form 483, listing 11 observations. Aurobindo Pharma characterised these observations as “procedural in nature.”